Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease
Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…A retrospective study on thyroid dysfunction mimicking Parkinsonian symptoms
Objective: This retrospective study analyzes outcomes of nine patients (three females, six males) admitted to the endocrinology department from 2020 to 2024. Initially diagnosed with…Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.
Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph…Trihexyphenidyl as a Treatment for Severe Freezing of Gait in Parkinson’s Disease: A Case Report
Objective: To present a unique case in which trihexyphenidyl was used as an effective treatment to dramatically reduce freezing of gait (FoG) in a Parkinson’s…Zonisamide for Motor Symptoms and OFF-Time Reduction in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy and safety of zonisamide as an adjunct therapy for improving motor function and reducing OFF-time in patients with Parkinson’s disease…Efficacy and Safety of Nicotine in Parkinson’s Disease: A Systematic Review and Meta-analysis
Objective: This systematic review and meta-analysis aimed to evaluate the safety and efficacy of nicotine compared with placebo in the treatment of Parkinson’s disease (PD).…The sphingolipid Lyso-Gb3, a biomarker for the lysosomal storage disorder Fabry Disease, is significantly elevated in blood from patients with Parkinson’s Disease
Objective: To better understand lysosomal dysfunction in Parkinson’s Disease. Background: Lysosomal dysfunction and α-synuclein accumulation play central roles in Parkinson’s Disease. They are interconnected by…Metabolomic breath landscape analysis unravels lipid biomarker candidates in patients with monogenic and idiopathic Parkinson’s disease
Objective: We propose an untargeted metabolomics approach using exhaled breath analysis to (1) characterize the non-volatile metabolomic breath signature of Parkinson’s disease (PD) patients with…Blood and CSF Biomarkers of Cognitive Impairment in Alpha Synucleinopathies
Objective: The aim was to investigate the role of both well-established and novel protein biomarkers of cognitive impairment in Parkinson’s disease (PD) and multiple system…Analyzing Longitudinal Correlation Between CSF Tau, Alpha-Synuclein, and Dysautonomia in Parkinson’s Disease Over Five Years
Objective: To examine the longitudinal association between tau, alpha-synuclein, and dysautonomia in Parkinson’s disease (PD). Background: PD is characterized by dopaminergic neural loss [1] and…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 436
- Next Page »